Prof. Barreca has 25-years of experience in the field of medicinal chemistry and drug discovery, and her main topics include infectious, neurodegenerative, and inflammatory diseases. She started her career at the University of Messina, where she founded a research laboratory in thefield of computational chemistry applied to drug discovery. In 2000−2001 Prof. Barreca was Visiting Scientist at the University of Houston and in 2007 she moved at the Department of Pharmaceutical Sciences of University of Perugia, where she set up and leads the I2D Lab (In silico Drug Discovery Laboratory) and she is Associate Professor. She has successfully collaborated to different multidisciplinary national and international projects where she made a crucial contribution to the rational identification and development of small molecules possessing the desired biological activity. Prof. Barreca has received awards and acknowledgments for her scientific activity, including the prestigious Italian&Farmindustria Prize for Pharmaceutical Research.
Prof. Barreca has identified bioactive small molecules which validate the innovative drug discovery protocol exploited by Sibylla Biotech S.R.L., which she co-founded in 2017.
Prof. Biasini received a broad education in pharmacology, biochemistry, molecular biology and neurobiology, with specific training and expertise in various aspects of neurodegenerative disorders. During his postdoctoral training at Washington University in St Louis, at the Mario Negri Institute in Milan, and later as a junior faculty at Boston University School of Medicine, he employed a variety of techniques of biochemistry and biophysics to elucidate basic principles of protein aggregation in several model systems, including cultured cell lines, primary neurons, neural stem cells and transgenic mice. For the last 5 years, as a group leader at the Italian National Institute of Health, and later as an Associate Professor at the Center for Integrative Biology (CIBIO), University of Trento, he built a team of young researchers with expertise in the fields of computational chemistry, biochemistry, biophysics and neurobiology. Work in the Biasini laboratory covers a wide spectrum of topics related to prions and amyloids, across physiology and disease, with the ultimate objective is to define novel therapeutic strategies for neurodegenerative disorders.
In 2017, by capitalizing on almost 20 years of research experience in the field, Prof. Biasini co-invented a novel cross-disciplinary technology for drug discovery and co-founded Sibylla Biotech S.R.L. to exploit the commercial potential of the invention.
Prof. Lolli started his scientific career in the field of Protein Chemistry and Proteomics to move then to Biophysical Chemistry and X-ray Crystallography.
His research activities focused on oncogenic proteins and epigenetics, participating in or directing drug development campaigns both in pharmaceutical companies and in academia. His multifaceted experience matured in highly competitive and production-driven environments having been employed by Pharmacia Corporation, University of Oxford, Merck&co., University of Padua and University of Zurich, in chronological order. The excellence of his work was recognized by the Federation of the European Biochemical Societies with the Distinguished Young Investigator Award. He currently directs a research team at the Centre for Integrative Biology, University of Trento, where he is Assistant Professor, developing novel drug candidates inhibiting protein kinases and bromodomains with a clear role in the pathogenesis of cancer, inflammation and neurodegenerative diseases. The laboratory employs a complete set of biochemical, biophysical and structural techniques.
His interest in fully exploring the targetable space drove its decision of founding Sibylla Biotech S.R.L., where the structure-based approach will profit from the revolutionary target identification protocol.
Pietro Faccioli received his PhD in theoretical physics from Stony Brook University (USA) with a thesis in subnuclear physics. Later he became a postdoctoral fellow at the European Centre for Nuclear Physics and Related Areas. In 2005 he was hired by University of Trento, where he is now Associate Professor and PI of a scientific initiative in biophysics of the Trento Institute for Nuclear and Subnuclear Physics (INFN-TIFPA). In 2005 he realized that a specific mathematical formalism used in subatomic physics could be adapted and extended in order to represent rare conformational transitions of macromolecules. This observation led to the creation of an interdisciplinary research line aiming at investigating the dynamics of biological molecules. In over 12 years of dedicated research, his group developed, validated and applied new powerful algorithms, which made it possible for the first time to simulate the folding of proteins consisting of hundreds of amino acids, using state of the art atomically resolved models.
This combination of mathematical and computational methods provided the driving technology paving the way to co-inventing a new approach to rational drug discovery. In 2017, he co-founded Sibylla Biotech S.R.L. to exploit the commercial potential of this invention.
Head of the Laboratory for Translational Genomics and Director of CIBIO, at the University of Trento.
Head of Laboratory of Synthetic and Structural Vaccinology (SSV) at CIBIO, University of Trento.
Head of the Laboratory for Neurogenomic Biomarkers at CIBIO, University of Trento. Formerly senior scientist at GSK and Roche
Head of the D3 Medicinal Chemistry laboratory and Director of the Pharmaceutical Chemistry Department at the University of Perugia.
Head of the Nanoscience laboratory at Physics Department of Trento University